CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $59.07, marking a -3.46% move from the previous day.

This year’s WIRED Health summit in Boston featured Moderna CEO Stéphane Bancel, CNN chief medical correspondent Sanjay Gupta, ...

Tulane University researchers have developed an enhanced CRISPR-based tuberculosis test that works with a simple tongue swab, ...

Academic, industry, and FDA collaboration is key to personalized treatment manufacturing, says Aldevron’s Max Sellman at BPI this week.

One of the biggest opportunities in healthcare today centers around genome editing. According to analysts at Grand View Research, the global genome market is expected to expand at a compound annual ...

The firm acquired intellectual property from Mammoth Biosciences that will reduce the speed and cost of its in-development point-of-care solution.

When brain development gets off to a bad start, the consequences are lifelong. One example is a condition called SCN2A ...

Researchers have developed a new AI tool to help scientists plan gene-editing experiments. "CRISPR-GPT" can help generate ...

An international multidisciplinary team has demonstrated for the first time that CRISPR-based gene activation (CRISPRa) can ...

A CRISPR mouth-swab test could transform TB screening with rapid, low-cost detection in low-resource and asymptomatic cases.